Gratwohl A, Baldomero H, Schmid O, Horisberger B, Bargetzi M, Urbano-Ispizua A
Hematology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.
Bone Marrow Transplant. 2005 Oct;36(7):575-90. doi: 10.1038/sj.bmt.1705104.
This EBMT activity survey presents the status of hematopoietic stem cell transplantation (HSCT) in Europe 2003 and focuses on changes in stem cell source over the last decade. There were 21 028 first HSCT, 7091 allogeneic (34%), 13 937 autologous (66%) and 4179 additional re- or multiple transplants reported from 597 centers in 42 European countries in the year 2003. Main indications were leukemias (6613 (31%; 78% allogeneic)); lymphomas (11 571 (55%; 93% autologous)); solid tumors (1792 (9%; 92% autologous)) and nonmalignant disorders (898 (5%; 93% allogeneic)). In 1991, the vast majority of autologous and all allogeneic HSCT were still bone marrow (BM) transplants. Stem cell source changed rapidly to peripheral blood (PB) for autologous HSCT between 1992 and 1996. In 2003, 97% of autologous HSCT were PB derived. The change to PB for allogeneic HSCT followed 3 years later and occurred at a lower rate. In 2003, 65% of all allogeneic HSCT were PB derived. The change in stem cell source was not homogeneous. It was associated with donor type, main diagnosis, disease stage and it differed between European countries. In 2003, bone marrow remains a significant source of stem cells in some European countries for autologous HSCT and for nonmalignant disorders in allogeneic HSCT.
这项欧洲血液和骨髓移植协会（EBMT）的活动调查展示了2003年欧洲造血干细胞移植（HSCT）的状况，并聚焦于过去十年间干细胞来源的变化。2003年，来自42个欧洲国家597个中心报告了21028例首次HSCT，其中7091例为异基因移植（34%），13937例为自体移植（66%），另有4179例再次或多次移植。主要适应证为白血病（6613例（31%；异基因移植占78%））；淋巴瘤（11571例（55%；自体移植占93%））；实体瘤（1792例（9%；自体移植占92%））和非恶性疾病（898例（5%；异基因移植占93%））。1991年，绝大多数自体和所有异基因HSCT仍为骨髓（BM）移植。1992年至1996年间，自体HSCT的干细胞来源迅速转变为外周血（PB）。2003年，97%的自体HSCT来源于PB。异基因HSCT向PB的转变在3年后出现，且发生率较低。2003年，65%的异基因HSCT来源于PB。干细胞来源的变化并不均匀。它与供体类型、主要诊断、疾病分期相关，且在欧洲国家之间存在差异。2003年，在一些欧洲国家，骨髓仍是自体HSCT以及异基因HSCT治疗非恶性疾病时干细胞的重要来源。
